16736151

Source:http://linkedlifedata.com/resource/pubmed/id/16736151

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0039736, umls-concept:C0201734, umls-concept:C0205390, umls-concept:C0205460, umls-concept:C0278883, umls-concept:C1135174, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2006-11-30
pubmed:abstractText	This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/U01-CA69853
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/SU 5416, http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0344-5704
pubmed:author	pubmed-author:BeeramMuralidharM, pubmed-author:BergKristinK, pubmed-author:EckhartS GailSG, pubmed-author:ForeroLeonardoL, pubmed-author:HammondLisa ALA, pubmed-author:IzbickaElzbietaE, pubmed-author:MitaAlain CAC, pubmed-author:MitaMonica MMM, pubmed-author:PatnaikAmitaA, pubmed-author:RowinskyEric KEK, pubmed-author:SimmonsPaulP, pubmed-author:TakimotoChrisC, pubmed-author:TolcherAnthony WAW, pubmed-author:WeissGeoffrey RGR, pubmed-author:de BonoJohann SJS
pubmed:issnType	Print
pubmed:volume	59
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	165-74
pubmed:dateRevised	2007-12-3
pubmed:meshHeading	pubmed-meshheading:16736151-Adult, pubmed-meshheading:16736151-Aged, pubmed-meshheading:16736151-Angiogenesis Inhibitors, pubmed-meshheading:16736151-Area Under Curve, pubmed-meshheading:16736151-Asthenia, pubmed-meshheading:16736151-Dose-Response Relationship, Drug, pubmed-meshheading:16736151-Edema, pubmed-meshheading:16736151-Female, pubmed-meshheading:16736151-Half-Life, pubmed-meshheading:16736151-Headache, pubmed-meshheading:16736151-Humans, pubmed-meshheading:16736151-Indoles, pubmed-meshheading:16736151-Male, pubmed-meshheading:16736151-Melanoma, pubmed-meshheading:16736151-Middle Aged, pubmed-meshheading:16736151-Neoplasm Metastasis, pubmed-meshheading:16736151-Peripheral Nervous System Diseases, pubmed-meshheading:16736151-Protein Kinase Inhibitors, pubmed-meshheading:16736151-Pyrroles, pubmed-meshheading:16736151-Thalidomide, pubmed-meshheading:16736151-Tumor Necrosis Factor-alpha, pubmed-meshheading:16736151-Vascular Endothelial Growth Factor A, pubmed-meshheading:16736151-Venous Thrombosis
pubmed:year	2007
pubmed:articleTitle	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
pubmed:affiliation	Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Phase II, Research Support, N.I.H., Extramural